
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/672582/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Use of a sparse sampling study design to assess transfer of tramadol and its O-desmethyl metabolite into transitional breast milk. British Journal of Clinical Pharmacology, 2008, 65, 661-666.	2.4	53
2	Mycobacterium tuberculosis Strains H37ra and H37rv have equivalent minimum inhibitory concentrations to most antituberculosis drugs. International Journal of Mycobacteriology, 2018, 7, 156.	0.6	48
3	Pharmacokinetics and pharmacodynamics in antibiotic dose optimization. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 93-114.	3.3	46
4	Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression. European Journal of Clinical Pharmacology, 2002, 58, 357-365.	1.9	38
5	Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4128-4139.	3.2	37
6	<i>In vitro</i> pharmacokinetics/pharmacodynamics of the combination of avibactam and aztreonam against MDR organisms. Journal of Antimicrobial Chemotherapy, 2016, 71, 1866-1880.	3.0	35
7	Population pharmacokinetic modeling of tramadol and its O-desmethyl metabolite in plasma and breast milk. European Journal of Clinical Pharmacology, 2011, 67, 899-908.	1.9	32
8	Pharmacokinetics of <i>para</i> -Aminosalicylic Acid in HIV-Uninfected and HIV-Coinfected Tuberculosis Patients Receiving Antiretroviral Therapy, Managed for Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2014, 58, 6242-6250.	3.2	31
9	Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime–Avibactam Combination: A Model-Informed Strategy for its Clinical Development. Clinical Pharmacokinetics, 2019, 58, 545-564.	3.5	30
10	Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	30
11	<i>N</i> -Acetyltransferase Genotypes and the Pharmacokinetics and Tolerability of <i>para</i> -Aminosalicylic Acid in Patients with Drug-Resistant Pulmonary Tuberculosis. Antimicrobial Agents and Chemotherapy, 2015, 59, 4129-4138.	3.2	27
12	Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	26
13	Prediction of <i>in vivo</i> and <i>in vitro</i> infection model results using a semimechanistic model of avibactam and aztreonam combination against multidrug resistant organisms. CPT: Pharmacometrics and Systems Pharmacology, 2017, 6, 197-207.	2.5	24
14	A mathematical model-based analysis of the time–kill kinetics of ceftazidime/avibactam against Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy, 2018, 73, 1295-1304.	3.0	24
15	Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant <i>Acinetobacter baumannii</i> Using Checkerboard Information. Microbial Drug Resistance, 2019, 25, 1266-1274.	2.0	23
16	Evaluation of in vitro synergy between vertilmicin and ceftazidime against Pseudomonas aeruginosa using a semi-mechanistic pharmacokinetic/pharmacodynamic model. International Journal of Antimicrobial Agents, 2015, 45, 151-160.	2.5	21
17	Gentamicin dosing strategy in patients with end-stage renal disease receiving haemodialysis: evaluation using a semi-mechanistic pharmacokinetic/pharmacodynamic model. Journal of Antimicrobial Chemotherapy, 2016, 71, 1012-1021.	3.0	21
18	Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors. Clinical Pharmacokinetics, 2017, 56, 65-76.	3.5	21

#	Article	IF	CITATIONS
19	Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation. International Journal of Antimicrobial Agents, 2019, 53, 275-283.	2.5	21
20	The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease. American Journal of Cardiovascular Drugs, 2003, 3, 101-112.	2.2	18
21	Potentiation of ceftazidime by avibactam against β-lactam-resistant <i>Pseudomonas aeruginosa</i> in an <i>in vitro</i> infection model. Journal of Antimicrobial Chemotherapy, 2017, 72, dkw535.	3.0	18
22	Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clinical Cancer Research, 2018, 24, 3348-3357.	7.0	18
23	Experimental design and modelling approach to evaluate efficacy of β-lactam/β-lactamase inhibitor combinations. Clinical Microbiology and Infection, 2018, 24, 707-715.	6.0	16
24	Simultaneous quantification of seven active metabolites of roxifiban in human plasma by LC/MS/MS in the presence of an interfering displacer at millimolar concentrations. Journal of Pharmaceutical and Biomedical Analysis, 2003, 31, 937-951.	2.8	15
25	Largazole Pharmacokinetics in Rats by LC-MS/MS. Marine Drugs, 2014, 12, 1623-1640.	4.6	15
26	Predicting Pediatric Age-Matched Weight and Body Mass Index. AAPS Journal, 2014, 16, 1372-1379.	4.4	15
27	Physiologicallyâ€based pharmacokinetics of ziprasidone in pregnant women. British Journal of Clinical Pharmacology, 2019, 85, 914-923.	2.4	15
28	Physiologically based pharmacokineticâ€pharmacodynamic evaluation of meropenem plus fosfomycin in paediatrics. British Journal of Clinical Pharmacology, 2021, 87, 1012-1023.	2.4	15
29	Characterization of intestinal absorption of C -glycoside flavonoid vicenin-2 from Lychnophora ericoides leafs in rats by nonlinear mixed effects modeling. Revista Brasileira De Farmacognosia, 2015, 25, 212-218.	1.4	14
30	Fixed-dose combinations: a potential means to boost drug development for selected drugs. Drug Discovery Today, 2018, 23, 457-459.	6.4	14
31	Aztreonam/avibactam effect on pharmacodynamic indices for mutant selection of <i>Escherichia coli and Klebsiella pneumoniae</i> harbouring serine- and New Delhi metallo-β-lactamases. Journal of Antimicrobial Chemotherapy, 2021, 76, 2875-2883.	3.0	14
32	A Markov Chain Model to Evaluate the Effect of CYP3A5 and ABCB1 Polymorphisms on Adverse Events Associated with Tacrolimus in Pediatric Renal Transplantation. AAPS Journal, 2013, 15, 1189-1199.	4.4	13
33	Pharmacometrics in Bacterial Infections. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 229-258.	0.6	13
34	Safety, Tolerability, Pharmacokinetics, and Time Course of Pharmacologic Response of the Active Metabolite of Roxifiban, XV459, a Glycoprotein IIb/IIIa Antagonist, following Oral Administration in Healthy Volunteers. Journal of Clinical Pharmacology, 2002, 42, 738-753.	2.0	12
35	Effect of reducing the paediatric stavudine dose by half: A physiologically-based pharmacokinetic model. International Journal of Antimicrobial Agents, 2015, 45, 413-419.	2.5	11
36	Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine. European Journal of Clinical Pharmacology, 2001, 57, 377-386.	1.9	10

#	Article	IF	CITATIONS
37	Principles of Applied Pharmacokinetic–Pharmacodynamic Modeling. , 2014, , 63-79.		10
38	Learning and augmenting natural processes: potential means of combating antimicrobial resistance from a drug R&D perspective. Drug Discovery Today, 2020, 25, 1-3.	6.4	10
39	Estimation of Intracellular Concentration of Stavudine Triphosphate in HIV-Infected Children Given a Reduced Dose of 0.5 Milligrams per Kilogram Twice Daily. Antimicrobial Agents and Chemotherapy, 2014, 58, 1084-1091.	3.2	9
40	Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development. AAPS Journal, 2018, 20, 40.	4.4	9
41	Introduction to Pharmacometrics and Quantitative Pharmacology with an Emphasis on Physiologically Based Pharmacokinetics. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 1-64.	0.6	8
42	Quantitation of the impact of <i>CYP3A5</i> A6986G polymorphism on quetiapine pharmacokinetics by simulation of target attainment. Clinical Pharmacology in Drug Development, 2015, 4, 387-394.	1.6	8
43	Pharmacokinetic Evaluation of Avicularin Using a Model-Based Development Approach. Planta Medica, 2015, 81, 373-381.	1.3	8
44	Simultaneous Characterization of Intravenous and Oral Pharmacokinetics of Lychnopholide in Rats by Transit Compartment Model. Planta Medica, 2015, 81, 1121-1127.	1.3	8
45	Exposure–Efficacy Analysis of Asciminib in Philadelphia Chromosome–Positive Chronic Myeloid Leukemia in Chronic Phase. Clinical Pharmacology and Therapeutics, 2022, 112, 1040-1050.	4.7	8
46	Pharmacokinetics I: PK-PD Approach, the Case of Antibiotic Drug Development. , 2016, , 185-217.		7
47	In silico labeling reveals the time-dependent label half-life and transit-time in dynamical systems. BMC Systems Biology, 2012, 6, 13.	3.0	6
48	Etirinotecan pegol administration is associated with lower incidences of neutropenia compared to irinotecan administration. Cancer Chemotherapy and Pharmacology, 2017, 79, 57-67.	2.3	6
49	Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases. Clinical Pharmacokinetics, 2022, 61, 1393-1403.	3.5	6
50	Influence of <i>CYP3A5</i> 6986A > G and <i>ABCB1</i> 3435C > T Polymorphisms on A Associated With Tacrolimus in Jordanian Pediatric Renal Transplant Patients. Clinical Pharmacology in Drug Development, 2013, 2, 67-78.	Adverse Ev 1.6	vents 5
51	Pharmacokinetics, Pharmacodynamics and Dermal Distribution of 5-Methoxypsoralen Based on a Physiologically Based Pharmacokinetic Model to Support Phytotherapy Using Brosimum gaudichaudii. Planta Medica, 2020, 86, 276-283.	1.3	5
52	Electroencephalogram effects of armodafinil: Comparison with behavioral alertness. Journal of Clinical Pharmacology, 2013, 53, 1058-1071.	2.0	4
53	Modelâ€informed drug development for immunoâ€oncology agonistic <scp>antiâ€GITR</scp> antibody <scp>GWN323</scp> : Dose selection based on <scp>MABEL</scp> and biologically active dose. Clinical and Translational Science, 2022, 15, 2218-2229.	3.1	4
54	Multivariate cluster analysis of a human hepatic cytochrome P 450 database. European Journal of Clinical Pharmacology, 2002, 58, 559-562.	1.9	3

#	Article	IF	CITATIONS
55	A Perspective on the Toxicological Mechanisms Possibly Contributing to the Failure of Oral Glycoprotein IIb/IIIa Antagonists in the Clinic. American Journal of Cardiovascular Drugs, 2004, 4, 1-10.	2.2	3
56	Florfenicol/Chlortetracycline Effect on Pharmacodynamic Indices for Mutant Selection of <i>Riemerella anatipestifer</i> in Ducks. Microbial Drug Resistance, 2022, 28, 832-840.	2.0	3
57	Rapid and efficient method for the quantification of lychnopholide in rat plasma by liquid chromatography–tandem mass spectrometry for pharmacokinetic application. Biomedical Chromatography, 2016, 30, 1092-1096.	1.7	2
58	Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors. Cancer Chemotherapy and Pharmacology, 2018, 81, 897-909.	2.3	2
59	Melanogenic Effect and Toxicity Assessments of Standardized Extract of Brosimum gaudichaudii. Revista Brasileira De Farmacognosia, 2020, 30, 597-601.	1.4	1
60	Application of Trial Simulation in the Design of a Prospective Study for Concentration-QTc Analysis in Support of a Thorough QT Study Waiver. AAPS Journal, 2020, 22, 101.	4.4	1
61	Pharmacokinetic-Pharmacodynamic Characterization of a Topical Photochemotherapy Using Brosimum gaudichaudii in C56BL/6 Mice. Revista Brasileira De Farmacognosia, 2021, 31, 184-192.	1.4	0